Romania’s Ministry of Health plans to change the clawback tax

Ovidiu Posirca 11/05/2017 | 11:51

Romania’s minister of health, Florian Bodog, says the government is looking to change the clawback tax, which has attracted criticism from the pharma industry in the past years.

The tax had been rolled out in 2009, in a bid to bring more money to the healthcare budget during the crisis period. Authorities had said that the tax was temporary, but is still enforced eight years later.

“Specialists in two ministries are working at an analysis on the clawback tax and the option to change it. Our government understands its impact on generic drugs producers and we agree that this burden of financial contributions has to be split evenly in the pharma industry,” the minister told Q Magazine.

“The philosophy of the Ministry of Health is simple: we want to ensure predictability and continuity on the pharma market for Romanian patients and I will not hesitate to take the best decisions so that they don’t run out of drugs,” added Bodog. The minister did not ellaborate on the potential changes to the tax and if there will be a different tax regime for producers of innovative and original drugs.

Earlier this week, Roche Romania, one of the producers of innovative drugs in Romania, said the clawback it paid in the first quarter reached close to 20 percent. The company said that there should be an independent audit of the data based on which this tax is computed.

Romania’s pharma market value gained more than 10 percent last year to EUR 2.8 billion.

BR Magazine | Latest Issue

Download PDF: Business Review Magazine March (II) 2024 Issue

The March (II) 2024 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “BAT DBS Romania Hub: A Vibrant New Office For An Employee-Centric
Ovidiu Posirca | 27/03/2024 | 17:32
Advertisement Advertisement
Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue